These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1093 related articles for article (PubMed ID: 26031544)

  • 41. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
    Chouhan H; Sammour T; Thomas ML; Moore JW
    J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.
    Kim JE; Hong YS; Ryu MH; Lee JL; Chang HM; Lim SB; Kim JH; Jang SJ; Kim MJ; Yu CS; Kang YK; Kim JC; Kim TW
    Cancer Sci; 2011 Sep; 102(9):1706-11. PubMed ID: 21679278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
    Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
    Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical relevance of microsatellite instability in colorectal cancer.
    de la Chapelle A; Hampel H
    J Clin Oncol; 2010 Jul; 28(20):3380-7. PubMed ID: 20516444
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Microsatellite instability. A new predictive marker (?)].
    Dietmaier W
    Pathologe; 2010 Oct; 31 Suppl 2():268-73. PubMed ID: 20824433
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
    Elsaleh H; Iacopetta B
    Clin Colorectal Cancer; 2001 Aug; 1(2):104-9. PubMed ID: 12445368
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An Insight into Deficient Mismatch Repair Colorectal Cancer Screening in a Romanian Population-A Bi-Institutional Pilot Study.
    Lungulescu C; Croitoru VM; Volovat SR; Cazacu IM; Turcu-Stiolica A; Gheonea DI; Sur D; Lungulescu CV
    Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441055
    [No Abstract]   [Full Text] [Related]  

  • 48. Molecular genetics of microsatellite-unstable colorectal cancer for pathologists.
    Chen W; Swanson BJ; Frankel WL
    Diagn Pathol; 2017 Mar; 12(1):24. PubMed ID: 28259170
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle.
    Tejpar S; Saridaki Z; Delorenzi M; Bosman F; Roth AD
    J Natl Cancer Inst; 2011 Jun; 103(11):841-4. PubMed ID: 21597023
    [No Abstract]   [Full Text] [Related]  

  • 50. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
    Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
    Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
    Storojeva I; Boulay JL; Heinimann K; Ballabeni P; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
    Oncol Rep; 2005 Jul; 14(1):241-9. PubMed ID: 15944796
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Colorectal cancer due to deficiency in DNA mismatch repair function: a review.
    Bellizzi AM; Frankel WL
    Adv Anat Pathol; 2009 Nov; 16(6):405-17. PubMed ID: 19851131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
    Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
    JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
    Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis.
    Tomasello G; Ghidini M; Galassi B; Grossi F; Luciani A; Petrelli F
    Sci Rep; 2022 Jan; 12(1):1055. PubMed ID: 35058539
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mismatch Repair Deficient (dMMR) Colorectal Carcinoma in a Pakistani Cohort: Association With Clinical and Pathological Parameters.
    Hashmi AA; Bukhari U; Rizwan R; Faisal F; Kumar R; Malik UA; Zia S; Khan AR; Sham S; Irfan M
    Cureus; 2023 Aug; 15(8):e42781. PubMed ID: 37664303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer.
    Sinicrope FA; Yang ZJ
    Future Oncol; 2011 Mar; 7(3):467-74. PubMed ID: 21417908
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Microsatellite Stable Colorectal Cancer With an Immunogenic Phenotype: Challenges in Diagnosis and Treatment.
    Saller J; Qin D; Felder S; Coppola D
    Clin Colorectal Cancer; 2020 Jun; 19(2):123-131. PubMed ID: 32171644
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
    Wang J; Li R; He Y; Yi Y; Wu H; Liang Z
    Mod Pathol; 2020 Dec; 33(12):2591-2601. PubMed ID: 32620917
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors.
    Svrcek M; Lascols O; Cohen R; Collura A; Jonchère V; Fléjou JF; Buhard O; Duval A
    Bull Cancer; 2019 Feb; 106(2):119-128. PubMed ID: 30713006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.